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Despite a high initial response rate to first-line platinum/paclitaxel chemotherapy, most women with epithelial ovarian cancer relapse
with recurrent disease that becomes refractory to further cytotoxic treatment. We have previously shown that the E3 ubiquitin ligase,
EDD, a regulator of DNA damage responses, is amplified and overexpressed in serous ovarian carcinoma. Given that DNA damage
pathways are linked to platinum resistance, the aim of this study was to determine if EDD expression was associated with disease
recurrence and platinum sensitivity in serous ovarian cancer. High nuclear EDD expression, as determined by immunohistochemistry
in a cohort of 151 women with serous ovarian carcinoma, was associated with an approximately two-fold increased risk of disease
recurrence and death in patients who initially responded to first-line chemotherapy, independently of disease stage and suboptimal
debulking. Although EDD expression was not directly correlated with relative cisplatin sensitivity of ovarian cancer cell lines, sensitivity
to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of
EDD expression. These results identify EDD as a new independent prognostic marker for outcome in serous ovarian cancer, and
suggest that pathways involving EDD, including DNA damage responses, may represent new therapeutic targets for chemoresistant
ovarian cancer.
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In developed countries, epithelial ovarian cancer is the leading
cause of death from gynaecological malignancies (Ries et al, 2007).
Typically, this cancer has an insidious onset and the majority of
women present with disease that has spread beyond the ovary.
Although a complete clinical response to optimal surgery and first-
line chemotherapy (currently usually a platinum agent in
combination with paclitaxel) is frequently achieved, the majority
of women will relapse with recurrent disease that becomes
refractory to further cytotoxic treatment and is essentially
incurable. Understanding the mechanisms that underlie the
emergence of drug resistance is critical for the development of
novel treatments that can prevent or overcome drug resistance and
thus improve survival (Vasey, 2003; Agarwal and Kaye, 2003).
The progestin-regulated HECT/E3 ubiquitin ligase EDD (E3
ligase identified by differential display; also called DD5, hHYD)i s
the human orthologue of the Drosophila melanogaster ‘hyper-
plastic discs’ tumour suppressor gene (Mansfield et al, 1994). Like
hyd, EDD encodes a large protein of approximately 300kDa that
contains a number of potential functional domains, including a
conserved carboxy terminus HECT domain with E3 ubiquitin
protein ligase activity (Callaghan et al, 1998). Mutagenesis studies
have revealed a critical role for hyd in the control of cell
proliferation during Drosophila development (Mansfield et al,
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s1994), suggesting that hyd functions as a tumour suppressor gene.
There is now substantial evidence that EDD is most likely involved
in the regulation of mammalian cell proliferation and human
tumorigenesis. First, ubiquitin-mediated proteolysis is essential for
the regulation of many key mammalian cellular pathways,
including control of cell cycle progression, transcriptional control
and DNA damage responses. Cancer-associated proteins identified
as being targeted by ubiquitinylation include tumour suppressors
such as p53, growth factor receptors, cell cycle regulators and
transcription factors (Burger and Seth, 2004). Moreover, there are
examples of E3 ligases themselves functioning as oncogenes
(Daujat et al, 2001) or tumour suppressor genes, including the
breast and ovarian cancer susceptibility gene BRCA1 (Hashizume
et al, 2001). HECT/E3 ligases can also function as steroid receptor
transcriptional co-activators (White and Parker, 1998), with a
proposed functional link to oncogenesis and hormone resistance.
We have previously shown that EDD has a role in progestin
signalling, being regulated both by progestin (Callaghan et al,
1998) and enhancing its transcriptional activity via a direct
interaction between EDD and the progestin receptor (Henderson
et al, 2002). We have also shown that EDD is a substrate of the
protein kinase ERK2, a component of the mitogen-activated
protein kinase pathway, critical to the regulation of many cellular
processes, including proliferation, differentiation, gene transcrip-
tion and cellular migration (Eblen et al, 2003). ERK can
phosphorylate EDD both in vitro and in vivo; however, the
phosphorylation sites in the EDD protein, likely to be numerous
given its large size, remain to be determined. Finally, results from
EDD knockout (Edd
D/D) mice have determined that EDD plays an
essential role in vascular development and angiogenesis (Saunders
et al, 2004).
Recent evidence from our laboratory has shown that EDD is also
involved in DNA damage signalling: it interacts with both the
DNA-dependent protein kinase-interacting protein CIB (Henderson
et al, 2002) and the cell checkpoint kinase CHK2, a critical
mediator of the cell cycle G2/M checkpoint in response to DNA
damage (Henderson et al, 2006), and is necessary for S-phase and
G2/M checkpoint proficiency following DNA damage (Munoz et al,
2007). To date, there is no evidence that these proteins are
ubiquitinylation substrates of EDD. Others have identified
topoisomerase IIb-binding protein, required for cell survival after
DNA damage (Yamane et al, 2002) and associated with an
increased risk of familial breast and ovarian cancer (Karppinen
et al, 2006), as a ubiquitinylation target of EDD (Honda et al,
2002).
We have previously shown that the EDD gene locus located at
8q22.3 exhibits a high frequency of allelic imbalance in a variety of
human cancers, including breast, liver and ovarian carcinoma
(Clancy et al, 2003). At least in breast and ovarian cancer, this
appears to be due to amplification, as demonstrated by EDD
overexpression in these tumours. Specifically, we demonstrated
that 47% of epithelial ovarian cancers exhibited allelic imbalance at
the EDD locus, which was rarely observed in benign and borderline
(low malignant potential) ovarian tumours and hence appears to
be restricted to malignant disease. The highest frequency of allelic
imbalance (73%) was found in serous ovarian carcinoma, the most
common histological subtype of ovarian cancer, which corre-
sponded to EDD expression in almost all of the cancers examined,
as determined by immunohistochemistry (IHC) (Clancy et al,
2003).
The aim of the current study was therefore to determine any
associations between EDD overexpression and patient outcome, in
particular disease recurrence in patients with serous ovarian
cancer, by correlating protein expression as measured by IHC to
clinicopathological parameters in a retrospective cohort of 151
primary cancers. In addition, given that the development of
resistance to platinum agents is linked to genes involved in DNA
damage response pathways (Richardson and Kaye, 2005), one of
the known functions of EDD, we also determined if EDD
expression was associated with sensitivity to cisplatin in serous
ovarian cancer.
MATERIALS AND METHODS
Tissue and clinicopathological data
Formalin-fixed, paraffin-embedded tissue specimens from 151
serous epithelial ovarian carcinomas were collected retrospectively
from patients undergoing primary laparatomy at the Gynaecolo-
gical Cancer Centre, Royal Hospital for Women between 1989 and
2002 following informed consent. Clinical (histopathologic diag-
nosis, treatment, surgical debulking), pathologic (tumour grade,
stage) and outcome (disease recurrence, death) data on each
patient were collected (Table 1). All experimental procedures were
approved by the Human Research Ethics Committee of the Sydney
South East Area Hospital Service, Eastern Section (00/115).
Immunohistochemistry
Tissue core biopsies of a minimum diameter of 1.0mm were
incorporated into medium-density tissue microarrays and
Table 1 Clinicopathological treatment, outcome and EDD expression
data for the serous ovarian cancer patient cohort (n¼151)
a
Variable n (%)
EDD expression
Low/absent (o6) 64 (42.4)
High (X6) 87 (57.6)
Age (years)
460 71 (47.0)
p60 80 (53.0)
FIGO Stage
I, II 16 (10.6)
III, IV 135 (89.4)
Tumour grade
1 7 (4.6)
2, 3 144 (95.4)
Surgical debulking
Optimal p1cm 89 (58.9)
Suboptimal 41cm 62 (41.1)
Menopausal status (n¼150)
Pre/peri 34 (22.7)
Post 116 (77.3)
CA125 (n¼128)
p500 54 (42.2)
4500 74 (57.8)
Adjuvant chemotherapy (n¼145)
P only 19 (13.1)
P+C 76 (52.5)
P+T 44 (30.3)
M only 6 (4.1)
Outcome
Complete response to treatment 114 (75.5)
Progressive disease 37 (24.5)
Recurrence
b 96 (84.2)
Death 123 (81.4)
C¼cyclophosphamide; M¼melphalan; P¼platinum; T¼paclitaxel.
an¼151 unless
otherwise stated.
bIn patients with complete response to treatment (n¼114).
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sdiagnosis confirmed by two gynaecological pathologists (JPS and
RAS) as described previously (Bali et al, 2004; Heinzelmann-
Schwarz et al, 2004). Tissue sectioning and IHC was performed as
previously described using a rabbit anti-EDD polyclonal antibody
(M19; Santa Cruz Biotechnology, Santa Cruz, CA, USA) (Clancy
et al, 2003). Negative control slides omitted the primary antibody.
In addition, embryonic neural tissue from wild-type (EDD
þ/þ)
and knockout (EDD
D/D) mice (Saunders et al, 2004) was used as
positive and negative controls, respectively.
Vascular endothelial growth factor (VEGF) staining was
performed using an anti-VEGF monoclonal antibody (Ab-3, clone
JH121; Neomarkers, Melbourne, VIC, Australia). Antigen retrieval
was performed in 10mM Tris/1mM EDTA (pH 9.0) at 1001C for
20min, followed by cooling at room temperature for 30min.
Antibody was used at 8mgml
 1 and incubated with the tissue
sections overnight at 41C. To visualise the antigen, sections were
incubated with biotinylated goat anti-mouse secondary antibody
(1:200), streptavidin–biotin–peroxidase complex (1:400) and
DAB chromogen as described previously (Zeng et al, 2004).
Immunohistochemistry staining for the cell cycle markers p53,
p21
Wap/Cif1, p27
Kip1, cyclin D1 and cyclin E in this cohort has been
reported previously (Bali et al, 2004).
Immunostaining was assessed by two independent observers
(including a gynaecological pathologist JPS) blinded to patient
stage and outcome and the discrepancies resolved by consensus.
Expression of EDD was scored as the percentage of positive-
staining nuclei (using assigned nominals: 0–25%¼1; 26–50%¼2;
51–75%¼3; 76–100%¼4) and intensity of staining (0–3), as
described previously (Clancy et al, 2003). Initial analysis of the
data showed that these parameters (% of positive nuclei and
intensity) were correlated and therefore we multiplied the score for
each sample to result in a scale of 0–12 indicative of the relative
expression of EDD. Examination of the range of staining across the
cohort determined a bimodal distribution around a median score
of 6, which also reflected mean expression. We therefore defined a
score of o6 as a low expression of EDD and X6 as a high level of
expression.
The percentage of cells and intensity of staining for cytoplasmic
VEGF expression was similarly scored. As almost all of the
carcinomas showed a high percentage of cells expressing VEGF
(median expression 93%), we defined high expression as intensity
of staining 42 based upon the median intensity of staining.
Scoring and thresholds for the cell cycle markers p53, p21
Wap/Cif1,
p27
Kip1, cyclin D1 and cyclin E in this cohort were as reported
previously (Bali et al, 2004).
Correlations between gene expression and clinical and patho-
logical variables were determined using the Mann–Whitney U test
using Statview 4.5 software (Abacus Systems, Berkeley, CA, USA).
A P-value of o0.05 was required for significance.
Correlation of EDD expression to patient outcome
Clinical and pathological variables (FIGO stage, grade, age,
menopausal status, optimal surgical debulking, chemotherapy
regime, pre-operative CA 125 levels), gene expression (VEGF, p53
and p21
Wap/Cif1) and EDD expression were correlated to patient
outcome using comprehensive clinical follow-up data for each
patient. Length of survival was defined from the date of initial
diagnosis to the date of patient death or, in the case of surviving
patients, their most recent follow-up date. For patients who
exhibited a complete response to treatment (defined as no clinical,
radiological or tumour marker evidence of disease for 3 months
post-treatment), recurrence-free survival was measured from the
date of diagnosis to the date of last follow-up or to disease
recurrence (defined as either the reappearance of clinical
symptoms by clinical examination or radiological investigation,
or a rising serum CA125 level 435Uml
 1). Overall survival was
defined as death due to ovarian cancer. Predictors of recurrence-
free or overall survival were evaluated by univariate and multi-
variate analyses by Kaplan–Meier analysis and Cox proportional
hazards models for dichotomised variables. Patients who had not
experienced an event (ie disease recurrence or death due to
ovarian cancer) at their most recent follow-up, or patients who
were lost to follow-up, were censored. All P-values corresponded to
two-sided tests, and Po0.05 was considered statistically signifi-
cant. All statistical analyses were performed using Statview 4.5
software (Abacus Systems).
Knockdown of EDD expression using siRNA
A2780/cp70 cells (Brown et al, 1993) were maintained in RPMI
1640 medium containing 10% FCS. For siRNA transfection,
5 10
5cells were seeded in 10cm dishes approximately 16h prior
to transfection and then transfected with 2.8pmolcm
 2 of siRNA
oligoribonucleotides using opti-MEM and Oligofectamine (Invi-
trogen Life Technologies, Mt Waverley, VIC, Australia). Annealed,
HPLC and PAGE-purified siRNA oligoribonucleotides were
obtained from Ambion (Austin, TX, USA): (EDD1) 50-GCAGUGUU
CCUGCCUUCUUdTdT-30 and (EDD2) 50-GCGACUCUCCAUGGU
UUCUdTdT-30. An siRNA directed against green fluorescent
protein (GFP) 50-CUGGAGUUGUCCCAAUUCUdTdT-30 was used
as a negative control. To confirm EDD knockdown, cells were
harvested 48h following transfection and whole lysates prepared
and used for western blotting.
Western blotting for EDD and CHK2 protein
SDS–PAGE and western blot analyses were performed according
to standard protocols. Briefly, cell lysates were prepared in
modified RIPA buffer (50mM Tris HCl (pH 7.4), 1% (v/v) NP40,
0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 137.5mM NaCl,
1% (v/v) glycerol and 0.5mM EDTA (pH 8.0) supplemented with
protease inhibitors 1mM sodium orthovanadate, 0.1mgml
 1
aprotinin, 0.5mgml
 1 leupeptin and 1mM phenylmethylsulphonyl
fluoride). To detect EDD protein, lysates (50mg) were electro-
phoresed on 6% polyacrylamide gels and transferred to PVDF
membrane for 2.5h. Membranes were blocked in 5% skim milk in
Tris-buffered saline/0.1% Tween, followed by incubation in rabbit
anti-EDD M19 antibody (1:10000) or rabbit EDD1 antibody
(1:10000; Bethyl Laboratories, Montgomery, TX, USA) overnight
at 41C. Detection of b-actin (1:40000 mouse anti-b-actin
monoclonal antibody; Sigma Aldrich, Castle Hill, NSW, Australia)
was used as a loading control. Following washing, membranes were
incubated with horseradish peroxidase-conjugated rabbit or
mouse anti-IgG antibody (1:10000; Amersham Biosciences,
Buckinghamshire, UK) for 1h at room temperature. Detection of
CHK2 protein using anti-CHK2 mouse monoclonal antibody
(0.5mgml
 1; Upstate, Lake Placid, NY, USA) was performed
according to the manufacturer’s protocol. For all membranes,
binding was detected using Western Lightning Chemolumines-
cence Reagent Plus (Perkin Elmer, Waltham, MA, USA) and
quantified by densitometry.
Colony-forming assays
Forty-eight hours following transfection with siRNA, 2–10 10
3
A2780-cp70 cells replated in six-well plates were treated with
0–100mM cisplatin (cis-diaminodichloroplatinum; Sigma Aldrich)
for 2h. Following replacement of the cisplatin with fresh media,
the plates were incubated for 6 days. Resulting colonies were
stained using DiffQuik (Lab Aids, Ronkonkoma, NY, USA) and
then scanned and quantified (ChemiDoc XRS and Quantity One
4.5.1; BioRad, Hercules, CA, USA). Results were expressed as the
relative percentage of colonies as compared to untreated controls
for each siRNA following adjustment for plating efficiency using
untreated wells.
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To calculate IC50, cell lines were seeded into 96-well plates in a
volume of 100 ml at 0.5–2 10
3cells per well and incubated at
371C overnight. On the following day, 50ml of complete medium
containing cisplatin was added to duplicate wells to give a final
drug concentration ranging from 625 to 20mM. Cell viability was
determined using MTS assay (Promega, Annandale, NSW,
Australia) on day 3 following drug treatment. Briefly, 100mlo f
PMS solution was mixed with 2ml of MTS solution, and 20ml was
added to each well. Following incubation at 371C for 1h,
absorbance was read at 490nm. IC50 values were calculated for
each cell line from survival curves using data generated from
between two and seven independent experiments. Correlation
between EDD, CHK2 and cisplatin IC50 was determined using
the Spearman rank correlation test using Statview 4.5 software
(Abacus Systems).
RESULTS
Correlation of EDD staining with patient
clinicopathological parameters
The clinicopathological treatment and outcome data of the patient
cohort are shown in Table 1. A total of 151 patients diagnosed with
serous epithelial ovarian carcinoma were examined. The majority
of women were post-menopausal (77.3%) presenting with high
(FIGO III–IV) stage (89.4%) serous ovarian carcinoma and treated
with platinum-based chemotherapy (95.9%; Table 1). Approxi-
mately, 75% (n¼114) of the patients had a complete response to
surgery and adjuvant chemotherapy (defined as no clinical,
radiological or tumour marker evidence of disease for 3 months
post-treatment). The remaining patients (n¼37, 25%) were
classified as having progressive disease (no or partial response to
surgery/chemotherapy, defined as a 50% reduction in tumour
volume or CA 125 levels). The median follow-up time for the
cohort was 35.5 months, with a median overall survival of 36.0
months. For patients with a complete response to treatment, the
median time to relapse was 15.4 months following surgical
diagnosis.
Expression of EDD protein was examined using IHC in archival
paraffin-embedded fixed primary cancer tissue sampled prior to
chemotherapy. The staining pattern of EDD was predominantly
nuclear, concordant with its cellular location, with a low level of
cytoplasmic staining in some cancers (Figure 1). EDD was
expressed in almost all of the carcinomas examined (n¼149/151,
98.7%), with 57.6% (n¼87/151) classified as having high nuclear
expression of EDD (overall score X6) (Table 1). EDD expression
in undiseased (normal) ovarian surface epithelium or inclusion
cysts, small foci of hyperplastic epithelium found within the cortex
of normal ovaries and proposed as the site of origin of epithelial
ovarian tumours (Auersperg et al, 2001), was rare (Figure 1). There
was no association between EDD staining and any of the
clinicopathological or gene expression variables tested, with the
exception of preoperative serum CA125 levels (Table 2).
EDD expression predicts disease recurrence and death
Kaplan–Meier analysis and a Cox proportional hazards model
were used to determine any associations between EDD expression
and patient outcome in the cohort of 151 patients. We first
examined the cohort of 114 patients who had initially responded to
treatment (‘complete response’) and thus were susceptible to
disease relapse. In this subgroup of patients, high FIGO stage (Cox
proportional hazards ratio (HR) 3.50, P¼0.002) and suboptimal
surgical debulking (HR 2.59, P¼o0.0001) were significantly
associated with disease recurrence in univariate analysis (Table 3).
Univariate analysis of EDD expression identified a significant
association between EDD expression and disease recurrence (HR
1.75, P¼0.011; Table 3) with a difference in median relapse time of
15.1 vs 17.3 months for patients with high and low EDD
expression, respectively (Figure 2A). When combined in a
multivariate model with FIGO stage and surgical debulking, the
most important clinical prognostic indicator of patient outcome in
AB
C D
Figure 1 Representative IHC results for EDD expression in (A), normal ovary (ovarian surface epithelium arrowed) and ovarian inclusion cysts (inset);
(B) negative EDD staining; (C) low (o6) EDD expression; and (D) high (X6) EDD expression in serous ovarian carcinomas. Original magnification  20.
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sovarian cancer, EDD expression, remained a significant predictor
of disease recurrence (HR 2.25, P¼0.0004; Table 3). A similar
association was found for high EDD expression and risk of death
in this group of patients (HR 1.77, P¼0.016), which was also
independent of FIGO stage and surgical debulking (HR 1.96,
P¼0.006; Table 3), and resulted in a difference in median overall
survival of 33.2 vs 42.5 months (Figure 2B). Moreover, if the
survival analysis was restricted to patients with high stage (FIGO
III/IV) and high tumour grade (grade 3) disease (n¼69), high
EDD expression was associated with an approximately four-fold
increased risk of recurrence (HR 4.87, Po0.0001) and death (HR
4.02, P¼0.003) following adjustment for surgical debulking.
We had previously shown that the cell cycle markers p53 and
p21
Wap/Cif1 were associated with disease recurrence in a subset of
these patients (Bali et al, 2004). Only p21
Wap/Cif1 retained its
significant association with disease recurrence in this expanded
cohort of patients (Table 3), and its incorporation into the
multivariate survival model did not affect the ability of EDD to
predict disease recurrence (HR 2.37, P¼0.0006) and survival (HR
2.35, P¼0.002).
There was no association of EDD expression with overall
survival in patients (n¼37) with progressive disease, that is
those who failed to respond to chemotherapy (Figure 2C). Hence,
the predictive effect of EDD expression on patient outcome may
be limited to patients who initially respond to treatment.
EDD expression is associated with resistance to cisplatin
As EDD plays a role in DNA damage response pathways, we next
tested if the ability of EDD expression to predict disease
recurrence, associated with the emergence of chemoresistance,
was related to the type of adjuvant chemotherapy received. There
was no association between EDD expression and response
to different chemotherapeutic agents (Table 2) and neither did
bivariate analysis of each treatment regime or individual chemo-
therapeutic agent (platinum, paclitaxel or alkylating agent
(cyclophosphamide or melphalan) alter the ability of EDD to
predict disease recurrence (data not shown). However, almost all
of the patients received similar adjuvant chemotherapy (ie
platinum-based therapy either alone or in combination), and
none of the regimes were associated with an enhanced survival
effect; hence, this cohort may not have sufficient power to perform
these analyses.
We, therefore, determined if EDD expression influences
response to chemotherapy in vitro. Given that platinum com-
pounds act via DNA damage pathways (Richardson and Kaye,
2005), we determined the effect of siRNA-mediated knockdown of
EDD mRNA expression on the cisplatin-resistant ovarian cancer
cell line A2780-cp70 following treatment with cisplatin. A2780-
cp70 cells transfected with siRNA targeting EDD mRNA were
approximately 40% more sensitive to cisplatin than those
transfected with a control siRNA (GFP) (Figure 3A and B). This
modified sensitivity to cisplatin was evident over a range of
Table 2 Correlation of EDD expression with clinicopathological and
gene expression variables
a
Variable P-value
b
Age 0.20
FIGO Stage 0.12
Tumour grade 0.17
Surgical debulking 0.59
Menopausal status 0.52
CA125 0.027
Adjuvant chemotherapy
P only 0.94
P+C 0.44
P+T 0.38
M only 0.97
VEGF 42 vs p2 0.80
p53 410% vs p10% 0.50
p27Kip1 p65% vs 465% 0.22
p21
Wap/Cif1 p10% vs 410% 0.22
Cyclin D1 410% vs p10% 0.90
Cyclin E 410% vs p10% 0.21
C¼cyclophosphamide; M¼melphalan; P¼platinum; T¼paclitaxel.
aEDD expres-
sion was modelled as a continuous variable. Clinicopathological and gene expression
variables were dichotomised as shown in Table 1, as described in the text (VEGF)
and Bali et al, 2004 (cell cycle markers).
bBold type indicates significant P-values.
Table 3 A, univariate and B, multivariate Cox proportional hazards
analyses of clinicopathological variables and gene expression with
recurrence-free survival and overall survival in patients that exhibited a
complete initial response to adjuvant chemotherapy
Recurrence-free survival Overall survival
Variable HR (95% CI) P-value
a HR (95% CI) P-value
(A)
Age (years)
p60 vs 460 0.95 (0.63–1.42) 0.80 0.79 (0.51–1.21) 0.28
FIGO stage
III/IV vs I/II 3.50 (1.61–7.61) 0.002 4.48 (1.80–11.15) 0.001
Tumour grade
2, 3 vs 1 2.54 (0.80–8.05) 0.11 2.55 (0.79–8.22) 0.12
Surgical debulking
41cmvs p1cm 2.59 (1.69–3.97) o0.0001 2.27 (1.46–3.52) 0.0001
Menopausal status
Post vs pre/peri 1.14 (0.72–1.80) 0.59 1.61 (0.94–2.74) 0.08
CA125
4500 vs p500 1.42 (0.90–2.22) 0.13 1.08 (0.68–1.71) 0.76
Adjuvant chemotherapy
P only N vs Y 1.38 (0.75–2.54) 0.29 1.14 (0.59–2.21) 0.70
P+C N vs Y 0.86 (0.57–1.29) 0.47 0.98 (0.64–1.51) 0.93
P+T N vs Y 0.90 (0.59–1.38) 0.63 0.93 (0.51–1.48) 0.76
M only N vs Y 1.95 (0.48–7.93) 0.35 1.25 (0.31–5.12) 0.76
EDD expression
High vs low/absent 1.75 (1.14–2.69) 0.011 1.77 (1.11–2.80) 0.016
VEGF expression
42 vs p2 1.39 (0.92–2.11) 0.12 1.22 (0.78–1.91) 0.38
p53 expression
410% vs p10% 1.31 (0.84–2.05) 0.24 1.09 (0.68–1.73) 0.73
p21
Wap/Cif1
o10% vs X10% 1.96 (1.03–3.74) 0.04 2.30 (1.14–4.63) 0.02
(B)
FIGO Stage
III/IV vs I/II 3.84 (1.74–8.48) 0.0009 4.61 (1.82–11.66) 0.001
Surgical debulking
41cmvs p1cm 2.60 (1.68–4.02) o0.0001 1.92 (1.23–3.00) 0.004
EDD expression
High vs low/absent 2.25 (1.44–3.52) 0.0004 1.96 (1.22–3.17) 0.006
C¼cyclophosphamide; CI¼confidence interval; HR¼hazards ratio; M¼melphalan;
P¼platinum; T, paclitaxel.
aBold type indicates significant P-values.
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scisplatin concentrations and was reproducible with two separate
siRNAs targeting different sequences of EDD mRNA (Figure 3C).
Together, these data show that ovarian cancer cells expressing high
levels of EDD are more resistant to cisplatin treatment than those
with low EDD expression.
As our survival modelling suggested that the prognostic effect of
EDD expression was limited to those patients who had a complete
response to their treatment, we hypothesised that EDD expression
may be associated with the acquisition of platinum resistance
rather than intrinsic chemoresistance in serous ovarian cancer
patients. To determine if there was a direct correlation between
EDD expression and cisplatin resistance, we compared the relative
cisplatin resistance (IC50) of six ovarian cancer cell lines of
differing histological subtypes to their levels of EDD protein as
determined by western blotting, as compared to the immortalised
ovarian surface epithelial cell line HOSE 17.1 (Table 4). There was
no correlation between EDD expression and cisplatin sensitivity
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Figure 3 Knockdown of EDD expression using siRNA inhibits growth of
cisplatin-resistant ovarian cancer cells. (A) Example of colony-forming assay
showing inhibition of growth of ovarian A2780-cp70 cells transfected with
siRNA against EDD (EDD siRNA1) as compared to siRNA against GFP
(control) following treatment with cisplatin (20mM); (B) A2780-cp70
colony number following treatment with cisplatin (20mM) 48h following
transfection with siRNA against GFP (control) or EDD (EDD siRNA1).
Results are expressed as the relative percentage of colonies as compared
to untreated controls for each siRNA following adjustment for plating
efficiency using untreated wells and are the means of duplicate
experiments, each performed in triplicate wells. Confirmation of reduced
EDD expression following siRNA transfection was determined by western
blotting (below). (C) Dose–response curve of a representative experi-
ment showing relative cisplatin sensitivity as determined by colony number
of A2780-cp70 cells transfected with siRNA against EDD (EDD siRNA 1
and siRNA 2) compared to cells transfected with siRNA against GFP
(control) after cisplatin treatment, as described above, and adjusted for
untreated controls.
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Figure 2 Association of EDD expression with ovarian cancer outcome.
Kaplan–Meier survival curves and log-rank P-values showing (A)
recurrence-free survival stratified by EDD expression (high vs low/absent)
in serous ovarian cancer patients who suffered disease recurrence following
initial complete response to treatment; (B) overall survival stratified by
EDD expression (high vs low/absent) in serous ovarian cancer patients who
suffered disease recurrence and death following initial complete response
to treatment; (C) overall survival stratified by EDD expression (high vs low/
absent) in patients with progressive disease (no or partial response to
treatment).
EDD predicts serous ovarian cancer recurrence
PM O’Brien et al
1090
British Journal of Cancer (2008) 98(6), 1085–1093 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(rs
2¼0.04, P¼0.65). Moreover, EDD expression was lower in the
cisplatin-resistant A2780-cp70 cell line than in its cisplatin-sensitive
parent line A2780 (Table 4). These data suggest that cisplatin
sensitivity is unlikely to be directly mediated by EDD but via cellular
pathways in which it is involved. As CHK2 has been previously shown
to be associated with cisplatin sensitivity in ovarian cancer (Zhang
et al, 2005), we hypothesised that the modulation of cisplatin
sensitivity by knockdown of EDD expression may be an indirect
effect caused by reduced EDD binding to CHK2. We did not,
however, find any association between EDD and CHK2 expression in
these cell lines (rs
2¼0.19, P¼0.34); however, CHK2 expression did
not significantly correlate with cisplatin resistance in our experiments
(rs
2¼0.49, P¼0.11).
To determine if the effect of EDD on cisplatin sensitivity was
potentially related to other functions of EDD other than DNA
damage repair pathways, specifically proliferation and angio-
genesis, we determined if EDD expression was correlated with cell
cycle markers or VEGF expression as measured by IHC in this
cohort of patients. There was no association between any of the cell
cycle markers examined or VEGF expression with EDD (Table 2),
suggesting that these functions of EDD are unlikely to be directly
involved in the observed effect on cisplatin sensitivity.
DISCUSSION
We have previously shown that EDD is specifically expressed in
ovarian epithelial carcinoma but not in normal ovarian epithelial
cells, which is most likely due to amplification at the EDD gene
locus as a result of genomic instability (Clancy et al, 2003). In
particular, high levels of EDD are expressed in the serous
histological subtype of ovarian cancer. In the current study, we
show that women exhibiting high EDD expression in their cancers
at the time of diagnosis and those having a complete response to
treatment (surgery and first-line chemotherapy) are approximately
two-fold more likely to relapse and die than those with low EDD
expression. This corresponded to a difference in median survival
of greater than 9 months. The predictive effect of EDD expression
on disease recurrence is independent of tumour stage or post-
operative residual disease, the most important clinical prognostic
indicators in serous ovarian cancer. Importantly, this correlated to
an approximately four-fold increased risk of disease recurrence
and death in patients with high stage, high-grade serous
carcinoma. These cancers are the most common presentation of
ovarian cancer and have a 5-year survival of approximately 20%
(Ries et al, 2007), and there are very limited prognostic indicators
in this group of patients (Birrer et al, 2007). This finding thus has
important clinical implications and further implicates the mole-
cular pathways in which EDD is involved as being important in
serous ovarian cancer pathogenesis. Although our data arise from
a large homogeneous cohort of well-characterised patients, these
findings require validation in independent patient cohorts.
Relapsed ovarian cancer is often refractory to further cytotoxic
treatment owing to the development of drug resistance. As in other
cancers, the emergence of chemoresistance in ovarian cancer is
linked to genes involved in DNA repair pathways, in particular to
resistance to cytotoxic agents that act by causing DNA damage
such as platinum compounds (Richardson and Kaye, 2005). For
example, expression of ERCC1 and XPA, components of the
nucleotide excision repair pathways, are associated with platinum
resistance in ovarian cancer (Damia et al, 1998; Selvakumaran
et al, 2003); methylation and silencing of the mismatch repair gene
MLH1 in some ovarian cancers also result in loss of cisplatin
sensitivity (Strathdee et al, 1999); and disruption of the FANC/
BRCA pathway by methylation of BRCA1 and FANCF alters
sensitivity to cisplatin in ovarian cancer (Taniguchi et al, 2003). As
one function of EDD is in the cellular response to DNA damage
(Henderson et al, 2002, 2006; Honda et al, 2002; Munoz et al,
2007), we postulated that the ability of EDD to predict disease
recurrence in serous ovarian cancer might similarly be related to
the emergence of chemoresistance. The survival curves for those
patients who initially responded to treatment were consistent with
this hypothesis: all of the patients had a similar survival rate until
approximately 12 months (disease recurrence) before diverging
into two groups based on EDD expression with clearly different
outcomes, suggestive of the emergence of chemoresistant cancer
cells. Although we were unable to determine an association of EDD
expression with response to chemotherapy, as almost all of the
patients in our cohort received platinum-based treatment, we did,
however, show that loss of EDD expression in a highly cisplatin-
resistant ovarian cancer cell line is associated with enhanced
sensitivity to cisplatin in vitro, thus supporting our hypothesis.
Therefore, ovarian cancer cells with high levels of EDD may have
an advantage in cell survival following chemotherapeutic attack by
having a more efficient response to DNA damage and thus emerge
as relapsed chemoresistant disease. We are currently undertaking
experiments to determine if EDD expression can modulate the
sensitivity to other classes of chemotherapy agents, including
microtubule-targeting agents such as paclitaxel, also used in
ovarian cancer.
Overexpression of DNA damage response proteins might be
expected to give cells an advantage following exposure to cytotoxic
drugs, such as platinum. For example, patients with non-functional
(mutated) BRCA1 or BRCA2, associated with hereditary breast and
ovarian cancer, respond better to platinum chemotherapy owing to
an increased sensitivity to DNA damage-induced cell death (Cass
et al, 2003). Reintroduction of BRCA1 into cells lacking functional
BRCA1 enhances resistance to both radiation and paclitaxel (Zhou
et al, 2003), and cells with higher than normal levels of BRCA1
protein are resistant to killing with platinum drugs (Husain et al,
1998). Similarly, ovarian cancers with high levels of EDD may be
more likely to survive cytotoxic chemotherapy, for example, via
the interaction between EDD and the critical DNA damage cell
cycle checkpoint kinase CHK2 (Henderson et al, 2006). CHK2
phosphorylates a number of key proteins (including BRCA1)
involved in various aspects of the DNA damage response including
cell cycle arrest at the G2/M checkpoint, DNA repair and apoptosis
(Motoyama and Naka, 2004). Degradation of CHK2 has been
linked to cisplatin-induced resistance in ovarian cancer cells
(Zhang et al, 2005), and alterations in the CHK2 pathway predict
poor prognosis in ovarian cancer (Hashiguchi et al, 2004). We did
not find an association between EDD and CHK2 expression in the
ovarian cancer cell lines examined. However, we also did not find a
correlation of CHK2 expression with cisplatin sensitivity, possibly
reflecting the relatively small number of cell lines analysed, and
thus it remains a possibility that the modulation of cisplatin
sensitivity observed in our EDD knockdown experiments is an
indirect effect caused by the interaction of EDD with CHK2.
Table 4 Correlation of relative EDD expression, relative CHK2
expression, and relative cisplatin sensitivity (IC50)
a of ovarian cancer cell
lines
b
Cell line Cisplatin IC50 EDD CHK2
HOSE17.1 0.90 1 1
CaOV3 1.20 (1) 0.30 (1) 3.78 (4)
OVCAR3 1.20 (1) 1.43 (5) 11.81 (6)
A2780 1.55 (3) 1.85 (6) 5.99 (5)
SKOV3 3.55 (4) 0.91 (4) 1.38 (1)
COLO316 11.20 (5) 0.53 (3) 3.43 (3)
A2780/cp70 13.60 (6) 0.37 (2) 2.44 (2)
aDetermination of IC50 is described in the Materials and methods.
bExpression was
determined by western blotting as described in the Materials and methods. Average
expression was calculated from duplicate blots and is expressed as relative values as
compared to HOSE17.1 cells. Ranks for the Spearman rank correlation test are
shown in brackets.
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may only be limited to patients who have a complete response to
their treatment, and that EDD expression has no prognostic effect
in women who are classified as being intrinsically resistant to
chemotherapy. Despite clear criteria, classification of patients into
complete and partial or non-responders to treatment remains
subjective, which may influence these data. Indeed, our in vitro
data did not support this hypothesis, as EDD expression was not
directly correlated to cisplatin sensitivity, at least in ovarian cancer
cell lines. Nonetheless, several gene expression profiling studies
have identified increased EDD expression associated with chemo-
resistance in ovarian and other cancers. Increased EDD mRNA
expression has been identified in post-chemotherapy carbo-
platinum-resistant serous ovarian cancer compared to post-chemo-
therapy sensitive carcinomas (Peters et al,2 0 0 5 ) ;i na c q u i r e d
cisplatin-resistant melanoma cell lines (Gyo ¨rffy et al,2 0 0 6 ) ;a n di n
secondary brain tumours in acute lymphoblastic leukaemia
patients arising following chemotherapy (Edick et al, 2005).
Moreover, although not specifically attributed to EDD, gains at
chromosome 8q12–23 are associated with development of
platinum resistance in serous ovarian cancer (Wasenius et al,
1997). These independent observations support and extend the
hypothesis that EDD overexpression is associated with acquired
but not intrinsic chemoresistance in ovarian and other tumour
types; however, this remains to be tested.
In addition to its role in cellular DNA repair, EDD has been
implicated in other biological pathways that are suggestive of a
functional link with ovarian cancer and that may additionally
influence its prognostic power. First, EDD plays a pivotal role in
the progesterone pathway, being both regulated by progestin and
directly binding the progestin receptor and enhancing its
transcriptional activity (Callaghan et al, 1998; Henderson et al,
2002). It has been known for several years that progesterone has a
protective effect on ovarian cancer, the mechanism attributed to a
reversal of the transformed phenotype including reduction of
cyclin-dependent kinase activity and increased Fas/FasL-induced
apoptosis (Blumenthal et al, 2003; Syed and Ho, 2003).
Secondly, we recently developed an EDD knockout mouse model
that determined a functional role of EDD in vascular development
and angiogenesis (Saunders et al, 2004). We predict that EDD
overexpression in cancer may therefore enhance the ability of
tumours to vascularise and spread. Marked neovascularisation is a
feature of malignant ascites, the most common dissemination
route of advanced serous ovarian cancer, and several angiogenic
markers, including VEGF, are highly overexpressed in ovarian
cancer (Ueda et al, 2005). We did not, however, find any
association between VEGF and EDD expression in this cohort of
patients, although such an association may become apparent in a
larger patient sample.
E3 ubiquitin ligases have been implicated in cancer development
via their regulation of key components of cellular pathways,
including control of cell cycle progression (Burger and Seth,
2004). Similar to VEGF, we did not find any association
between cell cycle markers and EDD expression in this cohort,
including the tumour suppressor p53, which is a key mediator
of cellular responses to DNA damage through modulation
of cell cycle regulation, DNA repair and activation of pathways
leading to apoptosis and is implicated in the development
of cisplatin-resistance in ovarian cancer (Kigawa et al, 2001).
Finally, although several ubiquitinylation targets of EDD have been
identified, the contribution of its E3 ligase function in ovarian
cancer is not yet known. Although somatic mutations in the EDD
gene have been reported in gastric and colorectal tumours
(Mori et al, 2002) and in mammary ductal carcinoma (Fuja et al,
2004), we have not identified any deleterious EDD mutations in a
number of ovarian cancer cell lines (Clancy et al, 2003), and
therefore, we predict that EDD mutation would be a very rare event
in ovarian cancer and hence assume that EDD is functional in
ovarian cancer.
In conclusion, although these findings remain to be validated in
independent cohorts, we have identified EDD as a new molecular
marker of prognosis in serous ovarian cancer, which may be
related to its role in DNA damage repair pathways. Determining
EDD expression levels may provide a clinically useful adjunct to
current criteria in the management of serous ovarian cancer
patients. Our observations that link EDD expression with platinum
sensitivity merit further investigation in other large cohorts of
serous ovarian cancer patients treated with adjuvant chemother-
apy on a prospective basis, particularly in the context of a
randomised treatment trial. Finally, E3 ubiquitin ligases have been
classified as suitable targets for a novel class of anticancer drugs
(Burger and Seth, 2004; Sun, 2006). Hence, EDD or DNA repair
pathways involving EDD may have future application as novel
therapeutic targets for patients who develop recurrent serous
ovarian cancer.
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